ArticleMolecular cancer therapeutics2018
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers.
Article in Molecular cancer therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform.Cellular & molecular biology letters · 2026Article
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
- "Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach".Frontiers in immunology · 2025Review
- High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy.Journal of clinical medicine · 2024Review
- Multi-Omic Analysis of Esophageal Adenocarcinoma Uncovers Candidate Therapeutic Targets and Cancer-Selective Posttranscriptional Regulation.Molecular & cellular proteomics : MCP · 2024Article
- Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.Journal of hematology & oncology · 2024Article
- Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.Heliyon · 2023Article
- Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells.Journal of visualized experiments : JoVE · 2023Article
- Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors.Frontiers in oncology · 2023Article
- Article
- Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.International journal of molecular sciences · 2022Review
- Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv.Scientific reports · 2022Article
- Review
- Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.Journal for immunotherapy of cancer · 2022Article
- Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.Journal for immunotherapy of cancer · 2021Article
- A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer.Biomedicines · 2021Article
- Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.Journal of biological engineering · 2021Article
- GPA33 is expressed on multiple human blood cell types and distinguishes CD4European journal of immunology · 2021Article
- Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.Journal for immunotherapy of cancer · 2021Article
- An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.Antibody therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Despite progress in the treatment of colorectal cancer, curing metastatic colorectal cancer remains a major unmet medical need worldwide. Here, we describe a T-cell-engaging bispecific antibody (T-BsAb) to redirect polyclonal cytotoxic T cells to eradicate colorectal cancer. A33, a murine antibody specific for GPA33, was humanized to huA33 and reformatted to huA33-BsAb, based on a novel IgG(L)-scFv platform by linking the anti-CD3 huOKT3 scFv to the carboxyl end of the light chain. This T-BsAb was stably expressed in CHO cells and purified as a stable monomer by HPLC, retaining immunoreactivity by FACS through 30 days of incubation at 37°C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.